SEATTLE--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced clinical and preclinical data from the company’s five lead antibody-based product candidates reported in multiple presentations during the American Society of Hematology (ASH) 48th Annual Meeting and Exposition in Orlando, Florida.
